Free Trial
NASDAQ:NBSE

NeuBase Therapeutics (NBSE) Stock Price, News & Analysis

$0.38
-0.01 (-3.20%)
(As of 05/10/2024)
Today's Range
$0.37
$0.39
50-Day Range
$0.38
$0.38
52-Week Range
$0.36
$4.80
Volume
97,700 shs
Average Volume
191,869 shs
Market Capitalization
$1.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NBSE stock logo

About NeuBase Therapeutics Stock (NASDAQ:NBSE)

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

NBSE Stock Price History

NBSE Stock News Headlines

Nvidia needs these 3 companies on a new $1 trillion Superproject
Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.
Nvidia needs these 3 companies on a new $1 trillion Superproject
Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.
NeuBase Therapeutics Inc
NeuBase Therapeutics, Inc. (NBSE)
NeuBase Therapeutics Inc (O7P.BE)
CMU halts licensing agreement with NeuBase Therapeutics
NeuBase Therapeutics Inc NBSE
NeuBase Therapeutics, Inc. (NBSE.MX)
Massive Insider Trade At NeuBase Therapeutics
See More Headlines
Receive NBSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/23/2021
Today
9/15/2024
Next Earnings (Estimated)
9/16/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NBSE
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$11.04 per share

Miscellaneous

Free Float
3,456,000
Market Cap
$1.43 million
Optionable
Not Optionable
Beta
0.81
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Todd P. Branning (Age 54)
    Interim CEO, CFO & Secretary
    Comp: $427.44k
  • Dr. Dietrich A. Stephan Ph.D. (Age 54)
    Founder, President & Director
    Comp: $836.58k

NBSE Stock Analysis - Frequently Asked Questions

How have NBSE shares performed this year?

NeuBase Therapeutics' stock was trading at $0.7401 at the beginning of 2024. Since then, NBSE stock has decreased by 48.7% and is now trading at $0.38.
View the best growth stocks for 2024 here
.

How were NeuBase Therapeutics' earnings last quarter?

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) posted its earnings results on Thursday, December, 23rd. The company reported ($4.20) EPS for the quarter, topping analysts' consensus estimates of ($4.60) by $0.40.

When did NeuBase Therapeutics' stock split?

NeuBase Therapeutics's stock reverse split on Thursday, June 15th 2023. The 1-20 reverse split was announced on Thursday, June 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of NeuBase Therapeutics?

Shares of NBSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of NeuBase Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuBase Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Flexion Therapeutics (FLXN) and Pfizer (PFE).

This page (NASDAQ:NBSE) was last updated on 9/16/2024 by MarketBeat.com Staff

From Our Partners